Poly (ADP-ribose) polymerase (PARP) inhibitors are a class of anti-cancer drugs that help treat cancers caused due to genetic mutations related to breast cancer susceptibility genes BRCA1 and BRCA2. These mutations cause DNA repair mechanism to dysfunction in cells, making them more sensitive to PARP inhibitors that prevent cancer cells from repairing damaged DNA through the process of PARP inhibition. The drugs are primarily used to treat breast, ovarian and prostate cancers.

The Global PARP Inhibitor Market Size is estimated to be valued at US$ 7.07 Mn in 2024 and is expected to exhibit a CAGR of 6.8% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
The PARP inhibitor market is expected to witness high growth owing to increasing prevalence of cancer globally. According to World Cancer Research Fund International, in 2020, around 19.3 million new cancer cases and 10 million cancer deaths were reported globally. Cancer burden is increasing rapidly both in developed and developing countries primarily due to lifestyle changes and expanding lifespan. With rising global cancer burden, demand for PARP inhibitors that are increasingly being used to treat cancer are also expected to rise significantly over the forecast period.

Additionally, increasing PARP inhibitor approvals for new cancer indications is also expected to boost market growth over the coming years. In 2021, Lynparza and Zejula were approved for the treatment of First-line maintenance treatment of BRCA-mutated advanced ovarian cancer in US and EU respectively. Recently, Talzenna was also approved for the treatment of certain metastatic breast cancers in US. With more approvals for new indications, usage and uptake of PARP inhibitors is estimated to rise sharply fueling overall market growth during the forecast period.

SWOT Analysis

Strength: PARP inhibitor drugs have shown promising results in the treatment of cancers with defective DNA damage repair mechanisms like BRCA1/2 mutations. Many pharmaceutical companies are investing in research and clinical trials to develop more effective and safer PARP inhibitors. Three or more approved drugs and many in the pipeline indicate a strong product portfolio.

Weakness: PARP inhibitors as monotherapy have limited success in patient groups without DNA repair deficiencies. Their use is also associated with side effects like fatigue, nausea, vomiting and bone marrow suppression. High costs of R&D and drug development pose challenges.

Opportunity: PARP inhibitors are being evaluated in combination with chemotherapy, immunotherapy and radiation therapy to expand the eligible patient population beyond hereditary cancers. Many ongoing clinical trials exploring new indications could boost the market size if successful. Personalized medicine approaches tailoring treatment to an individual's genetic profile offer growth prospects.

Threats: Competition from other emerging targeted cancer therapies poses a threat. Failure or delays in late stage clinical trials could negatively impact drug approvals and market potential. Dependence on a few key drugs makes the market vulnerable to generic competition on patent expiration. Stringent regulatory processes for new drug approvals also introduce uncertainties.


Key Takeaways

The global PARP inhibitor market is expected to witness high growth over the forecast period of 2024-2031 driven by ongoing clinical research and new drug approvals. The global PARP inhibitor market is estimated to be valued at US$ 7.07 Mn in 2024 and is expected to exhibit a CAGR of 6.8% over the forecast period 2024 to 2031.

Currently the US and major European countries dominate the market due to their advanced healthcare infrastructures and high adoption of premium-priced cancer drugs. However, Asia Pacific region is projected to experience the fastest growth during this period supported by growing healthcare expenditure, increasing cancer incidence, and rising affordability in several emerging economies. The North American region currently has the largest share in the global PARP inhibitors market led by the US which approves most new targeted cancer therapies and has favorable reimbursement policies. Europe is the second largest market with major countries like Germany, UK and France contributing significantly. Asia Pacific region provides lucrative opportunities with China, India, Japan and South Korea expected to witness rapid gains due to expanding healthcare sector, growing middle class with medical insurance, and changing consumer attitudes favoring targeted therapies over chemotherapy.

Key players: Key players operating in the PARP inhibitor market are FLSmidth & Co. A/S, Metso Oyj, Koppern Group, CITIC Heavy Industries Co. Ltd. (CITIC HIC), ThyssenKrupp Industrial Solutions AG (Polysius AG), SGS S.A., KHD Humboldt Wedag International AG, Outotec Oyj, and ABB Ltd.

Get More Insights on This Topic: https://insightinferno24.blogspot.com/2024/02/parp-inhibitor-market-growth.html 

Explore More Information, Please Visit: https://coolbio.org/understanding-human-embryonic-stem-cells/